Moberg Pharma Extends Distribution Agreement with Menarini

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 9, 2015 at 2:45 AM

Moberg Pharma Extends Distribution Agreement with Menarini Group for Emtrix to Russia

STOCKHOLM, February 9, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine. The extended distribution agreement builds on an existing collaboration between Moberg and Menarini, which resulted in a successful launch of Emtrix® in Italy and most recently, the expansion to China and Southeast Asia where product launches have been initiated. The rights to Emtrix® in Russia were released from a previous distribution agreement with Meda AB. The product was not launched in Russia under the previous agreement. Berlin-Chemie/Menarini is a leading regional biopharmaceutical company with full national coverage in Russia, a sales force with more than 700 sales representatives and a strong track record of launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3.3 billion Euros. Russia and Ukraine comprise almost 200 million people and represent a significant long-term growth opportunity for Moberg Pharma. “I am very pleased to expand our collaboration with the Menarini Group through this agreement with Berlin-Chemie – a leading marketer in Eastern Europe. The Russian market has significant long-term potential for Moberg’s products,” said Peter Wolpert, CEO of Moberg Pharma AB. “We look forward to introducing Emtrix® to consumers in Russia. The product has potential to contribute strongly to our expansion within the Consumer Health market, as it provides rapid relief for a large segment of patients suffering from nail fungus”, said Michael Sirotovich, COO at Berlin-Chemie AG’s International Division. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 am (CET) on February 9, 2015. About Emtrix® and nail disease Emtrix is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best -selling product in its category in the U.S. The international launch is under way via a proprietary sales organization in the U.S. and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia. Emtrix is a prescription-free, over-the-counter product sold under the names Kerasal Nail®, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments. For additional information, please contact: Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail: peter.wolpert@mobergpharma.se Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se About Moberg Pharma Moberg Pharma AB (MOB.ST) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail®(Nalox™/ Emtrix®in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The strategy to expand the portfolio includes acquisitions and in -licensing, as well as internal development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com. About Menarini Group The Menarini Group is the number one Italian pharmaceutical company in the world, 16th in Europe out of 5,291 companies, and 36th company in the world out of 19,042 companies, with a turnover of more than 3,3 billion Euro and more than 16,600 employees. The Menarini Group has always pursued two strategic objectives: Research and Internationalisation and is present in the most important therapeutic areas including products for cardiology, gastroenterology, pneumology/antibiotics, diabetology, antinflammatory agents/analgesics. With 14 production sites and 5 Research and Development centres, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini’s products are available in more than 100 countries worldwide. For further information please visit www.menarini.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ARPwave Therapy: A Game Changer For Patient Recovery

New Insights in Recovery with ARPwave Therapy Getting stuck in a rehab rut is not uncommon. That's where ARPwave therapy steps in, taking an innovative approach to healing by focusing on the nervous system's role in recovery. Props to Jeff Kessler from Maximum Health Physical Therapy for shedding light on this game-changing method during an insightful piece in...

Sophont's Holon-S1: Revolutionizing Pathology and AI

Pushing Boundaries in Tumor Analysis with AI In the world of medical AI, it's not every day you hear about a tool that claims to read the secrets hidden within routine pathology slides to predict tumor behavior. Yet, here we are with Sophont's latest brainchild, the Holon-S1. This thing is more than just another AI model; it's a giant leap towards pulling the veil off...

AHN Opens Clinic for Severe Postpartum Tear Care

A Game Changer for Postpartum Recovery When it comes to childbirth, you think you've heard it all, but here's a twist—Allegheny Health Network (AHN) just swung the doors open on a clinic laser-focused on a very raw deal: third- and fourth-degree perineal lacerations. We're diving into new territory where one network sees the gap and jumps into action, calling in the...

Norwegian Bella™: A New Era in Luxury Cruising

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

DARPA Pumps $10.7M into RxMP's Hemorrhage Control Drug

RxMP Therapeutics Lands a DARPA Deal Would you look at that—RxMP Therapeutics just got handed a load of cash thanks to some good old government backing. Up to $10.7 million from DARPA is no chump change. It's like finding a lifeboat right when you're treading water out there in the big bad sea. This award under the RAPIID program is set to move the needle for RxMP’s...

FAA Greenlights Boeing’s 737-10: What’s at Stake?

Breaking New Ground: Boeing 737-10 Certified Well, the folks at Boeing must be popping champagne, because the U.S. Federal Aviation Administration (FAA) just handed them the golden ticket: certification for the brand spankin' new Boeing 737-10. This ain't your average paper-pushing approval. We're talking nearly 1,000 test flights and what seems like a mountain of safety...

STEM Grant Boosts Outdoor Learning in Shelbyville

Supporting Future Leaders in STEM Some news is like finding a hidden gem in your backyard. This one comes from the hushed fields of Shelbyville, Indiana, where Girls Inc. of Shelbyville is making waves with a $25,000 grant from the American Water Charitable Foundation. It's no surprise that Indiana American Water is celebrating this landmark move, given that they're...

Florida Poly's Astro: First Flying Police Vehicle Takes Off

Flying Into A New Era of Campus Safety Hold onto your hats, folks, because we're catapulting straight into the future. Florida Polytechnic University just rolled out something straight from sci-fi flicks—a flying police car. Yep, you heard right. They've dubbed it 'Astro,' after that lovable pooch from the Jetsons. Pioneering Advanced Air Mobility The Florida...

BMO's Bold Leadership Shuffle: Cox Takes Helm

Fresh Blood at the Helm: Tim Cox's New Role BMO's leadership is getting a shakeup worthy of any Wall Street drama. Tim Cox, a name insiders hail for his sharp legal mind and strategic chops, is stepping up as the U.S. Country Head for BMO. Come November 1st, he'll be steering BMO's massive U.S. subsidiaries like BMO Financial Corp. and BMO Bank N.A. It's a big leap from...

AI Agents Race: 10M Downloads Spark Competitive Fire

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...